Sight Sciences wins FDA 510(k) clearance for OMNI Ultra glaucoma system
Sight Sciences has received FDA 510(k) clearance for the OMNI Ultra Surgical System, a next-generation minimally invasive glaucoma surgery (MIGS) device designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The Nasdaq-listed company said a US commercial launch remains on track for the fourth quarter of 2026.
OMNI Ultra performs canaloplasty followed by trabeculotomy through a single clear corneal microincision, targeting all three known areas of conventional aqueous outflow resistance: the trabecular meshwork, Schlemm's canal, and the collector channels. The system carries no implant, positioning it as an alternative to stent-based approaches that can complicate future surgical options. A key feature is TruSync Plus technology, which the company says provides automatic, controlled viscodilation as the microcatheter advances and retracts, completing a full circumferential canaloplasty in a single pass. Sight Sciences describes this as the first FDA-cleared MIGS device to achieve that in a single pass, though the claim has not been independently verified.
Paul Badawi, co-founder and chief executive of Sight Sciences, said the clearance "marks an important milestone reflecting our continued investment and meaningful innovation," adding that the platform is intended to help surgeons "intervene earlier and more comprehensively" as glaucoma remains the world's leading cause of irreversible blindness.
Platform heritage and commercial context
OMNI Ultra is positioned as an evolution of the existing OMNI platform rather than a wholesale replacement. Sight Sciences reports that more than 350,000 procedures have been performed globally across its OMNI device family, providing a substantial installed base from which to drive adoption of the new system. The device can be used as a standalone procedure or alongside cataract surgery, the latter representing a high-volume setting that has historically been the primary commercial channel for MIGS.
The broader MIGS market has grown markedly over the past decade as ophthalmologists and their patients look to reduce reliance on daily topical medications, which carry adherence challenges and cumulative side-effect burdens. Competing platforms from Alcon, Glaukos, and iStent-aligned device companies occupy the implant-based segment, while Sight Sciences has consistently differentiated on the implant-free positioning. How surgeons weigh procedural efficiency gains in OMNI Ultra against established familiarity with incumbent systems will be the central commercial question for the launch period.
Regulatory and competitive read-across
The 510(k) pathway, which grants clearance based on substantial equivalence to a predicate device rather than requiring the larger clinical dataset demanded by a PMA, is standard for iterative MIGS hardware. Clearance of OMNI Ultra does not require Sight Sciences to present new randomised controlled trial data, though the company notes that the broader OMNI platform is supported by prospective, real-world, and long-term studies demonstrating reductions in IOP and medication burden.
For investors, the near-term focus will be the Q4 2026 launch execution and its contribution to revenue guidance. Sight Sciences has faced revenue headwinds in prior periods as payer coverage for MIGS procedures evolved, and uptake of OMNI Ultra will depend in part on whether reimbursement codes established for earlier OMNI generations extend cleanly to the new system. Surgeons familiar with the existing platform are the most accessible early adopters, with broader market expansion hinging on training programmes and clinical publication of device-specific outcome data.